Pfizer and the $200 Billion-Dollar Cardiovascular Market

Cardiovascular disease remains the world's leading cause of death, making treatments for heart disease among the pharmaceutical industry's most valuable assets. Analysts expect the global cardiovascular drug market to exceed $200 billion by 2033, driven by ageing populations, better diagnosis and the arrival of new precision medicines.

That enormous commercial opportunity has created an industry where scientific innovation sits alongside fierce legal, commercial and marketing competition. As blockbuster drugs compete for physician adoption, reimbursement and long-term market share, companies increasingly battle not only in the laboratory but also in courtrooms, before regulators and through marketing campaigns. While breakthrough therapies have extended and improved countless lives, critics argue that the race for market dominance has also encouraged aggressive patent strategies, controversial marketing and pricing practices that have repeatedly drawn regulatory scrutiny.

Few companies illustrate these tensions more clearly than Pfizer.

Pricing, Co-Pays and the Kickbacks: Pfizer's ATTR-CM therapies

Pricing has become one of the industry's most contentious issues.

ATTR-CM therapies illustrate the challenge. Pfizer's Vyndaqel and Vyndamax have annual list prices approaching $268,000 in the US, placing them among the most expensive cardiovascular medicines available.

In 2021, Pfizer sought permission to directly cover Medicare patients' co-payments for these drugs, arguing that many patients faced unaffordable out-of-pocket costs despite insurance coverage.

Pfizer argued the program would improve patient access to life-saving medicines. The US Government, however, argued that allowing manufacturers to pay patients' co-payments would undermine safeguards designed to prevent companies from insulating patients from high prices. Government lawyers contended that removing patients' financial responsibility could weaken one of the few remaining market pressures limiting drug prices while increasing costs borne by Medicare.

In 2022, a federal appeals court sided with the government, concluding that Pfizer's proposed programme would violate the US Anti-Kickback Statute because it could induce purchases reimbursed by federal healthcare programmes. The ruling marked a significant setback for Pfizer's efforts to expand access to its high-cost ATTR-CM medicines, while reinforcing regulators' concerns that manufacturer-funded financial assistance could also strengthen demand for specific blockbuster therapies.

Pfizer's Misleading Marketing Claims Over Vyndamax

Marketing has long been another area where pharmaceutical companies have faced criticism, and Pfizer has previously been involved in one of the largest enforcement actions in America's pharmaceutical history. In 2009, the company agreed to pay $2.3 billion to resolve criminal and civil investigations into the promotion of several medicines, with a Pfizer subsidiary pleading guilty to the felony misbranding of the painkiller Bextra.

The case remains a defining example in debates over pharmaceutical promotion. That history provides important context for the fast-growing ATTR-CM market, where Pfizer's tafamidis franchise now faces increasing competition from companies including BridgeBio and Alnylam. Last year, a German court ruling required Pfizer to stop describing Vyndamax as providing "near-complete stabilisation" of transthyretin after the court concluded that claim was not supported by the available evidence or the product label.

In high-value therapeutic areas, even subtle differences in how medicines are promoted can influence physician perceptions, prescribing patterns and ultimately market share. That is why the increasingly competitive ATTR-CM market has become a focal point for disputes over promotional claims.

The case of Eliquis: Anti-Competition and Patents

Pfizer's approach to protecting blockbuster cardiovascular medicines is also evident with Eliquis (apixaban), which it co-markets with Bristol Myers Squibb.

Although Eliquis' primary US patent expires in 2026, a series of patent disputes and legal settlements means competing versions are not expected to enter the market until April 2028. Pfizer and Bristol Myers Squibb maintain they are enforcing valid intellectual property rights, while critics argue such strategies can prolong market exclusivity and limit competition.

Eliquis has also been the subject of product liability lawsuits in which class action lawyers raised concerns over bleeding risks and the drug's safety profile, allegations the companies have disputed. Such disputes raise a broader question for the cardiovascular market: when blockbuster medicines dominate for extended periods, how can regulators encourage the competition needed to drive the next generation of safer and more effective treatments?

The Bigger Picture

Pfizer's pricing disputes, marketing controversies and patent litigation reflect different facets of one of the pharmaceutical industry's most commercially valuable markets. Collectively, they illustrate how key segments of the cardiovascular sector can become concentrated around a small number of blockbuster medicines, with competition extending beyond scientific innovation to legal strategy, regulatory disputes and the defence of market exclusivity.

This dynamic can make it more difficult for both new entrants and established competitors to challenge incumbent products, potentially reducing the competitive pressure that can encourage innovation, improve treatments and broaden patient choice within the cardiovascular market.

Whatever the balance between innovation and commercial strategy, patients ultimately have the greatest stake in ensuring the market delivers safe, effective and affordable treatments.